Drug safety: who is responsible? by Pitt, B.
3 Taddei S, Ghiadoni L. Phosphodiesterase 5 inhibition to treat
hypertension: is this the beginning of the story? Hypertension 2006;
48: 546–8.
4 Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J
Clin Pract 2006; 60: 1123–6.
5 Oliver JJ. Diabetic neuropathy – a further indication for phosphodi-
esterase type 5 inhibition? Int J Clin Pract 2006; 60: 1026–7.
6 Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testoster-
one in the treatment of erectile dysfunction. Int J Clin Pract 2006;
60: 1087–92.
7 Jackson G. Testosterone – not just a replacement therapy. Int J Clin
Pract 2006; 60: 1021–2.
doi: 10.1111/j.1742-1241.2006.01257.x
ED ITORIAL
Drug safety: who is responsible?
Both the lay and medical press have been inundated
with articles reporting the risk of drugs such as
Vioxx, Celebrex and Natrecor. Industry has been
accused of suppressing unfavourable data and mis-
leading physicians and patients as to their true risks.
Journals have been criticised for publication of incom-
plete safety data and not being rigorous in their review
process. The Food and Drug Administration (FDA)
has been accused of inadequate drug approval and
surveillance policies. These highly publicised issues
have elicited calls for reform of how clinical research
studies are designed, funded and reported; calls for
reorganisation of the FDA; and greater independence
of clinical investigators from industry. Such discus-
sions are appropriate and will hopefully lead to more
timely and responsible information on drug safety.
It is true that in many instances physicians and
their patients have been exposed to unnecessary risk
because of the lack of reliable information provided
by industry and the FDA. There are, however, also
instances in which despite adequate information on
safety physicians have misused or misapplied existing
drugs resulting in adverse events. Randomised pla-
cebo-controlled clinical trials serve as the basis for
evidence-based medicine. Their results are, however,
often inappropriately or not applied to clinical prac-
tice. Life-saving therapies such as statins, angiotensin
converting enzyme–inhibitors and beta adrenergic
blocking agents are underused in patients shown to
benefit from these strategies. On the other hand, cli-
nicians when extrapolating the results of randomised
trials to patient groups not directly studied in the
clinical trial may not heed the important inclusion/
exclusion criteria and monitoring parameters which
contributed to the net risk/benefit of the interven-
tion. Consider, for example the use of the aldoster-
one blocker spironolactone. The Randomised
Aldactone Evaluation Study (RALES) (1) showed
that patients with severe heart failure because of sys-
tolic left ventricular dysfunction (SLVD) when rand-
omised to spironolactone at a mean dose of 26 mg/
day had a significant reduction in total mortality.
Patients were excluded from enrollment into RALES
(1) if they had renal insufficiency or an increase in
serum potassium and it was emphasised that serum
creatinine may be an inadequate guide to renal func-
tion, especially in the elderly (2). Also of importance
was the fact that in RALES (1) the patients’ serum
potassium was closely monitored and the dose of
spironolactone adjusted accordingly. With these pre-
cautions the incidence of hyperkalemia in RALES (1)
was <2% and not associated with any deaths.
The strategy of aldosterone blockade for patients
with severe heart failure because of SLVD has been
incorporated into both USA and European guidelines
(3,4). These recommendations have however been
accompanied by reports suggesting that when spir-
onolactone is used in clinical practice it is associated
with a high incidence of hyperkalemia often resulting
in renal dysfunction, the need for dialysis and occa-
sionally death (5–7,6). These reports have prompted
the suggestion that the use of spironolactone be
restricted to specialised multidisciplinary pro-
grammes of chronic-disease management (8) and
have generated the concept in some physicians minds
that the use of spironolactone in patients with severe
heart failure because of SLVD is dangerous and best
avoided.
In my opinion spironolactone per se is not ‘dan-
gerous’ but rather how physicians have applied and
monitored its use. Unfortunately, some physicians
did not heed the recommendations in RALES (1)
and administered spironolactone to patients with
renal dysfunction, and/or an increase in serum potas-
sium, often at doses greater than recommended in
RALES. Most importantly, they did not monitor
serum potassium or adjust the dose of spironolac-
tone accordingly. For example in one report (7) of
patients given spironolactone for heart failure there
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approximately 1/3 of patients administered spirono-
lactone, there was not a single measurement of
serum potassium. Consider as an analogy the use of
Coumadin to prevent stroke in patients with atrial
fibrillation: one would consider it malpractice if a
patient receiving Coumadin suffered a cerebral
haemorrhage without a single measurement of their
prothromin time. Coumadin, like spironolactone has
known risks that are relatively infrequent and pale in
comparison with its benefits when given to appropri-
ate patients and properly monitored.
The explanation for the failure of some physicians
to use spironolactone properly is complex but likely
includes the fact that it is generic and therefore has
been the focus of relatively little postgraduate physi-
cian or patient education from the pharmaceutical
industry (9). The education of the physician is how-
ever not the responsibility of the pharmaceutical
industry but of organised medicine, medical schools
and government. The failure of physicians to prop-
erly use and monitor spironolactone is unfortunately
not unique and not necessarily related to the fact
that it is generic. For example, there is evidence that
physicians did not heed warnings with regard to
troglitazone with regard to monitoring hepatic func-
tion, resulting in unnecessary episodes of liver failure
and death (10). Despite the known toxicity of amio-
darone, some physicians do not monitor pulmonary,
hepatic or thyroid function and do not give patients
advice about avoiding exposure to the sun (11).
Medication monitoring errors are a common cause
of preventable adverse drug reactions (12) and physi-
cians frequently prescribe drugs with ‘black box’
warnings in their labels without taking proper pre-
cautions or informing the patient as to the risks
(13). Other explanations include increased pressure
on physician’s time, including administrative efforts
related to third party care; decreased per patient
reimbursement, and the resultant need to increase
patient volume and throughput. The rapid pace of
medical advances makes it difficult for the practicing
physician to keep abreast of optimum current prac-
tice and details of drug administration and safety.
Similarly, there is increased pressure on the time
available to teach house staff and medical students
about the drug dosing and safety. Bedside teaching
rounds including detailed discussions about drug
usage and safety have been curtailed in many institu-
tions because of the limitations imposed on house
staff availability (14).
The recent problems with drug safety have increased
public and governmental scrutiny and led to recom-
mendations for reforms by industry, journals and the
FDA. While these efforts are important we also need
to reform postgraduate, house staff and undergraduate
medical education as well as to provide the practicing
physician the time and tools to appropriately adminis-
ter drugs so as to minimise their risks. Simplification
of drug labelling, computer-based drug ordering sys-
tems, computer-based reference systems and academic
detailing may alleviate some of the problems alluded
to above but are unlikely to eliminate the need for bet-
ter physician education and practice. New incentives
need to be implemented to encourage proper drug
use. No effective drug is free of risk. We need to be
better informed as to their potential risks and when
informed need to heed the recommendations. Drug
safety is not only the responsibility of industry, jour-
nals and regulatory agencies, but also medical educa-
tors, and the practicing physician. Unless we all do a
better job in correcting the problems outlined above
many potentially lifesaving drugs will be discarded or
under and overused resulting in unnecessary suffering
and costs. In the hands of an informed physician and
patient many ‘dangerous drugs’ if appropriately
administered and monitored could be life and cost
saving.
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Sexual assault includes rape – that is, vaginal, anal or
oral intercourse which is physically forced or which
occurs when consent was not capable of being given,
including as a result of intoxication – and other
types of physically forced sexual contact and verbally
coerced sexual intercourse (1,2). In a groundbreaking
1987 American study, Koss et al. (3) found that sex-
ual assault was surprisingly common; in a survey of
around 6000 college students, a quarter of the men
admitted to having carried out a sexual assault since
the age of 14 years, while over half the women
reported having experienced sexual assault since the
age of 14 years. The human impact of these shocking
figures was underlined by the 1992 publication of a
brave and moving paper, entitled ‘Rape and Respon-
sibility’ by Lynne Henderson (4), in which she star-
ted with the following introduction:
‘‘I am a ‘lucky’ survivor of a rape committed by a
stranger – ‘lucky’, because people believed in me, a
jury convicted the man of raping me, and he is still
in prison 10 years later. I know many women who
have been raped who were not so fortunate, because
they believed the rape was their fault, because no
one else believed them, because they knew their
rapist, or because they were married to him and it
was not a crime. We share some things – the anger,
the pain, the anguish, the fear – and not others; nev-
ertheless, this is what I wished after I was raped and
still wish: never again, not for any woman. Rape is
evil’’.
In the years since the publication of Henderson’s
paper, which gives an American perspective in
respect of legislation, the issue of consensual sexual
activity has become even more given to the phenom-
enon of drug-facilitated sexual assault using what are
commonly described as ‘date-rape drugs’. This is the
subject of the detailed paper by Papadodima et al.
(5) which appears in this month’s issue of the Inter-
national Journal of Clinical Practice. In their paper,
which gives a Greek viewpoint in relation to legisla-
tion, Papadodima et al. mention the main substances
that have been implicated in drug-facilitated sexual
assaults, including alcohol, benzodiazepines, gamma-
hydroxybutyric acid (GHB), ketamine, scopolamine,
barbiturates, opiates, cannabis, muscle relaxants,
antihistamines, chloral hydrate, amphetamines and
cocaine.
To this list may be added ecstasy (E or 3,4-methy-
lenedioxymethamphetamine; MDMA). It has been
suggested that, in court, it may be that ‘date rape’
prosecutions may be more likely to rely on evidence
from toxicologists, pathologists and police officers,
who find MDMA and amphetamines in samples
taken from victims of sexual assault, rather than on
the testimony of psychiatrists and psychologists who
may understand the effects on humans of these drugs
and who may apparently dismiss claims that MDMA
is a date-rape drug as a myth propagated by the
media (6).
In any case, it does not appear to be a myth that
another class of drugs, the benzodiazepines, may be
used as date rape drugs. Benzodiazepines are a par-
ticular cause of concern, owing to their ability not
only to induce relaxation but also to play tricks on
the memory (7). Indeed, the association of the rap-
idly acting and essentially colourless and odourless
hypnotic benzodiazepine flunitrazepam with
date rape by being used to ‘spike’ drinks led the
manufacturer Hoffmann-La-Roche to revise its for-
mulation of Rohypnol so that it now dissolves less
quickly and contains a blue dye designed to manifest
itself if the drug is added to a drink.
Certain psychiatric disorders and personality traits
may be associated with the perpetration of drug-faci-
litated sexual assault. Alcohol is likely to be the drug
most commonly used in this way. In a recent Ameri-
can study of 356 male students comparing alcohol-
involved perpetrators of sexual assault with both
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